Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

miR-10b-5p Suppresses the Proliferation and Invasion of Primary Hepatic Carcinoma Cells by Downregulating EphA2.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
  • المؤلفون: Niu X;Niu X; Sun H; Sun H; Qiu F; Qiu F; Liu J; Liu J; Yang T; Yang T; Han W; Han W
  • المصدر:
    BioMed research international [Biomed Res Int] 2021 Dec 29; Vol. 2021, pp. 1382061. Date of Electronic Publication: 2021 Dec 29 (Print Publication: 2021).
  • نوع النشر :
    Journal Article; Retracted Publication
  • اللغة:
    English
  • معلومة اضافية
    • المصدر:
      Publisher: Hindawi Pub. Co Country of Publication: United States NLM ID: 101600173 Publication Model: eCollection Cited Medium: Internet ISSN: 2314-6141 (Electronic) NLM ISO Abbreviation: Biomed Res Int Subsets: MEDLINE
    • بيانات النشر:
      Original Publication: New York, NY : Hindawi Pub. Co.
    • الموضوع:
      Carcinoma, Hepatocellular/*genetics ; Cell Proliferation/*genetics ; Down-Regulation/*genetics ; Liver Neoplasms/*genetics ; MicroRNAs/*genetics ; Neoplasm Invasiveness/*genetics ; Receptor, EphA2/*genetics; Apoptosis/genetics ; Carcinoma, Hepatocellular/pathology ; Cell Line, Tumor ; Cell Movement/genetics ; Erythropoietin/genetics ; Gene Expression Regulation, Neoplastic/genetics ; Hep G2 Cells ; Humans ; Liver Neoplasms/pathology ; Neoplasm Invasiveness/pathology ; Transfection/methods ; Up-Regulation/genetics
    • نبذة مختصرة :
      Objective: To analyze the function of miR-10b-5p in suppressing the invasion and proliferation of primary hepatic carcinoma cells by downregulating erythropoietin-producing hepatocellular receptor A2 (EphA2). Material and Methods . Eighty-six hepatic carcinoma (HCC) tissue specimens and 86 corresponding adjacent tissue specimens were collected, and the mRNA expression of miR-10b-5p and Ephrin type-A receptor 2 (EphA2) in the specimens was determined using a reverse transcription-polymerase chain reaction (RT-PCR) assay. Western blot was employed to quantify EphA2, B-cell chronic lymphocytic leukemia/lymphoma-2 (Bcl-2), Bcl-2-associated X protein (Bax), and Caspase-3 in the cells, and CCK8, Transwell assay, and flow cytometry were applied to evaluate the proliferation, invasion, and apoptosis of cells, respectively. Moreover, the dual luciferase reporter assay was utilized for correlation analysis between miR-10b-5p and EphA2.
      Results: miR-10b-5p was lowly expressed in HCC, while EphA2 was highly expressed. Cell experiments revealed that miR-10b-5p overexpression or EphA2 knockdown could reduce cell proliferation, accelerate apoptosis, strongly upregulate Bax and Caspase-3, and downregulate Bcl-2. In contrast, miR-10b-5p knockdown or EphA2 overexpression gave rise to reverse biological phenotypes. Furthermore, dual luciferase reporter assay verified that miR-10b-5p was a target of EphA2, and the rescue experiment implied that transfection of pCMV-EphA2 or Si-EphA2 could reverse EphA2 expression and cell biological functions caused by miR-10b-5p overexpression or knockdown.
      Conclusions: miR-10b-5p reduced HCC cell proliferation but accelerate apoptosis by regulating EphA2, suggesting it has the potential to be a clinical target for HCC.
      Competing Interests: The authors declare no conflict of interest.
      (Copyright © 2021 Xu Niu et al.)
    • Comments:
      Retraction in: Biomed Res Int. 2024 Mar 20;2024:9834789. (PMID: 38550032)
    • References:
      Genomics. 1997 Mar 1;40(2):371-4. (PMID: 9119409)
      Hepatology. 2018 May;67(5):1857-1871. (PMID: 29159818)
      J Cancer. 2018 Aug 6;9(17):3109-3116. (PMID: 30210634)
      Cell Death Dis. 2018 Feb 15;9(3):283. (PMID: 29449527)
      PLoS One. 2013 Jun 18;8(6):e66165. (PMID: 23824282)
      Cancer Causes Control. 2018 Sep;29(9):833-844. (PMID: 30030669)
      Mol Ther Nucleic Acids. 2019 Mar 1;14:239-250. (PMID: 30641476)
      Anticancer Agents Med Chem. 2018;18(12):1688-1694. (PMID: 29384062)
      Int J Biochem Cell Biol. 2014 Aug;53:208-17. (PMID: 24875649)
      Liver Cancer. 2019 Oct;8(5):312-325. (PMID: 31768342)
      Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2018 Dec;34(12):1091-1098. (PMID: 30626475)
      Hepatol Res. 2009 Dec;39(12):1169-77. (PMID: 19788698)
      Eur Rev Med Pharmacol Sci. 2018 Dec;22(23):8431-8437. (PMID: 30556884)
      Semin Cancer Biol. 2019 Apr;55:120-127. (PMID: 29605648)
      Biochem Biophys Res Commun. 2019 Nov 19;519(4):846-853. (PMID: 31558317)
      Cancer Res. 2011 May 15;71(10):3563-72. (PMID: 21471404)
      Oncol Lett. 2019 Feb;17(2):2317-2327. (PMID: 30675297)
      Biomed Pharmacother. 2019 Jan;109:991-999. (PMID: 30551553)
      PeerJ. 2019 Sep 20;7:e7728. (PMID: 31579605)
      Oncol Rep. 2016 Apr;35(4):1967-78. (PMID: 26796749)
      Exp Ther Med. 2019 Jun;17(6):4577-4585. (PMID: 31105788)
      Int J Clin Exp Pathol. 2015 May 01;8(5):4782-90. (PMID: 26191168)
      Dig Dis Sci. 2019 Jun;64(6):1523-1534. (PMID: 30604369)
    • الرقم المعرف:
      0 (EPHA2 protein, human)
      0 (MIRN10 microRNA, human)
      0 (MicroRNAs)
      11096-26-7 (Erythropoietin)
      EC 2.7.10.1 (Receptor, EphA2)
    • الموضوع:
      Date Created: 20220110 Date Completed: 20220114 Latest Revision: 20240329
    • الموضوع:
      20240329
    • الرقم المعرف:
      PMC8731268
    • الرقم المعرف:
      10.1155/2021/1382061
    • الرقم المعرف:
      35005012